IL150222A0 - Pharmaceutical compositions containing a gepirone metabolite - Google Patents

Pharmaceutical compositions containing a gepirone metabolite

Info

Publication number
IL150222A0
IL150222A0 IL15022200A IL15022200A IL150222A0 IL 150222 A0 IL150222 A0 IL 150222A0 IL 15022200 A IL15022200 A IL 15022200A IL 15022200 A IL15022200 A IL 15022200A IL 150222 A0 IL150222 A0 IL 150222A0
Authority
IL
Israel
Prior art keywords
gepirone
pharmaceutical compositions
compositions containing
gepirone metabolite
metabolite
Prior art date
Application number
IL15022200A
Other languages
English (en)
Inventor
Edward H Ruediger
Joseph P Yevich
Original Assignee
Fabre Kramer Pharmaceuticals I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Kramer Pharmaceuticals I filed Critical Fabre Kramer Pharmaceuticals I
Publication of IL150222A0 publication Critical patent/IL150222A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15022200A 1999-12-20 2000-12-18 Pharmaceutical compositions containing a gepirone metabolite IL150222A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17268499P 1999-12-20 1999-12-20
US09/709,741 US6534507B1 (en) 1999-12-20 2000-11-13 Methods for treating psychological disorders using bioactive metabolites of gepirone
PCT/US2000/034131 WO2001045687A2 (en) 1999-12-20 2000-12-18 Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Publications (1)

Publication Number Publication Date
IL150222A0 true IL150222A0 (en) 2002-12-01

Family

ID=26868346

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15022200A IL150222A0 (en) 1999-12-20 2000-12-18 Pharmaceutical compositions containing a gepirone metabolite
IL150222A IL150222A (en) 1999-12-20 2002-06-13 Pharmaceutical preparations containing Gifiron metabolism

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150222A IL150222A (en) 1999-12-20 2002-06-13 Pharmaceutical preparations containing Gifiron metabolism

Country Status (20)

Country Link
US (1) US6534507B1 (xx)
EP (1) EP1242061B1 (xx)
JP (1) JP4236407B2 (xx)
KR (1) KR100602976B1 (xx)
CN (1) CN1411375A (xx)
AT (1) ATE294572T1 (xx)
AU (1) AU776409B2 (xx)
CA (1) CA2395458C (xx)
CZ (1) CZ300429B6 (xx)
DE (1) DE60019968T2 (xx)
ES (1) ES2241683T3 (xx)
HU (1) HU228963B1 (xx)
IL (2) IL150222A0 (xx)
MX (1) MXPA02006146A (xx)
NO (1) NO323304B1 (xx)
NZ (1) NZ519554A (xx)
PL (1) PL200378B1 (xx)
PT (1) PT1242061E (xx)
RU (1) RU2282448C2 (xx)
WO (1) WO2001045687A2 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295478A1 (en) * 2000-08-22 2002-03-04 Akzo Nobel N.V. Active metabolite of gepirone
US20040000689A1 (en) * 2002-06-28 2004-01-01 Erh-Kun Lai Dual-bit MONOS/SONOS memory structure with non-continuous floating gate
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
CA2495659A1 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Process for hydroxyazapirones
WO2004069339A1 (en) * 2003-01-29 2004-08-19 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
TW200521125A (en) * 2003-11-18 2005-07-01 Bristol Myers Squibb Co Continuous process for producing hydroxyazapirones by oxidation
EA013213B1 (ru) * 2004-11-05 2010-04-30 Фэйбр-Крэймер Холдингз, Инк. Дозированная форма биоактивного метаболита гепирона с высокой дозировкой и длительным высвобождением, способ ее получения и способ лечения депрессии с ее использованием
CN102026639A (zh) * 2008-05-08 2011-04-20 法布雷－克雷默医药公司 用于治疗注意力缺陷障碍和性功能障碍的3-羟基吉哌隆

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5478572A (en) 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
PL200378B1 (pl) 2008-12-31
PT1242061E (pt) 2005-09-30
AU2268701A (en) 2001-07-03
RU2002119400A (ru) 2004-01-27
DE60019968D1 (de) 2005-06-09
NZ519554A (en) 2005-01-28
AU776409B2 (en) 2004-09-09
EP1242061A2 (en) 2002-09-25
JP4236407B2 (ja) 2009-03-11
CZ20022137A3 (cs) 2003-03-12
JP2004500362A (ja) 2004-01-08
IL150222A (en) 2009-09-22
HU228963B1 (en) 2013-07-29
MXPA02006146A (es) 2004-08-23
WO2001045687A2 (en) 2001-06-28
US6534507B1 (en) 2003-03-18
PL364936A1 (en) 2004-12-27
NO323304B1 (no) 2007-03-05
RU2282448C2 (ru) 2006-08-27
NO20022954L (no) 2002-06-19
EP1242061B1 (en) 2005-05-04
CN1411375A (zh) 2003-04-16
ES2241683T3 (es) 2005-11-01
DE60019968T2 (de) 2006-02-02
HUP0301831A2 (hu) 2003-09-29
WO2001045687A3 (en) 2002-04-25
KR20020082470A (ko) 2002-10-31
NO20022954D0 (no) 2002-06-19
ATE294572T1 (de) 2005-05-15
CA2395458A1 (en) 2001-06-28
CZ300429B6 (cs) 2009-05-20
CA2395458C (en) 2009-05-12
KR100602976B1 (ko) 2006-07-20

Similar Documents

Publication Publication Date Title
AU711212B2 (en) Methods for treating allergic disorders using (-) cetirizine
FR21C1010I1 (xx)
AU2002360462A1 (en) Compositions containing both sedative and non-sedative antihistamines
KR970704435A (ko) 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands)
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
HUP0201275A3 (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts and pharmaceutical composition containing the compound
KR20170007868A (ko) Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법
IL150222A0 (en) Pharmaceutical compositions containing a gepirone metabolite
MY129450A (en) Pharmaceutical composition
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
EP1256344A4 (en) REMEDIES FOR ENDOTHELIN-INDUCED DISEASES
CA2145413A1 (en) Methods and compositions for treating allergic disorders using optically pure (+) cetirizine
PE20011004A1 (es) Composicion de liberacion controlada de un inhibidor de fosfodiesterasa 4
RU2002118304A (ru) Способ подавления чувства страха
CA2364178A1 (en) N-benzenesulfonyl l-proline compounds as bradykinin antagonists
IL148777A (en) Mirtazepine oral oral administration unit
MY143571A (en) Eplerenone crystalline form
ES2076894A1 (es) Derivados de 2-(4-(4-azolibutil)-1-piperacinil)-5-hidroxipirimidina, su preparacion y su aplicacion como medicamentos.
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
JPS5942316A (ja) 睡眠障害治療剤
FR2696741B1 (fr) Dérivés de 1-(4-chlorophényl)-2-[4-[(4-fluorophényl)méthyl]piperidin-1-yl] éthanol, leur préparation et leur application en thérapeutique.
WO2002072100A3 (en) Pharmaceutical composition containing pde v inhibitors and surfactants
AU703690B2 (en) Methods for treating allergic disorders using optically pure (+)cetirizine